Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
61,248.59 -1,650.14 (-2.62%) CMC Crypto 200
1,305.13 +10.45 (+0.81%)
Gossamer Bio, Inc. (GOSS)
After hours:
| Previous close | 0.7315 |
| Open | 0.7600 |
| Bid | 0.7532 x 100 |
| Ask | 0.7945 x 200 |
| Day's range | 0.7330 - 0.8078 |
| 52-week range | 0.4530 - 1.8800 |
| Volume | |
| Avg. volume | 1,684,877 |
| Market cap | 170.886M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1800 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.09 |
Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 07, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
BenzingaGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement to develop and commercialize seralutinib. This global collaboration combines the strengths of both Chiesi and Gossamer to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate the development of pulmonary hypertension associated with interstitial lung disease (PH-ILD). “Seralutinib is a potential paradigm-shifting therapy in PAH and PH-ILD,
- Reuters
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. Gossamer is to receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.
